Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Ophthalmol Retina ; 6(10): 922-929, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35483614

RESUMO

PURPOSE: To evaluate long-term visual acuity (VA) and performance of a monitoring strategy with a self-operated artificial-intelligence-enabled home monitoring system in conjunction with standard care for early detection of neovascular age-related macular degeneration (nAMD). DESIGN: Retrospective review. SUBJECTS: Patients with dry-age-related macular degeneration from 5 referral clinics. METHODS: Clinical data of patients monitored with ForeseeHome (FSH) device from August 2010 to July 2020 were reviewed. MAIN OUTCOME MEASURES: Visual acuity at baseline, VA at diagnosis of nAMD for eyes that converted while monitored, and VA from the final study follow-up, weekly frequency of use, duration of monitoring, modality of conversion diagnosis (system alert vs. detection by other standard care means), and duration and number of treatments since conversion to final study follow-up were collected. RESULTS: We reviewed 3334 eyes of 2123 patients with a mean (standard deviation [SD]) age of 74(8) years, monitored for a mean (SD) duration of 3.1 (2.4) years, with a total of 1 706 433 tests in 10 474 eye-monitoring years. The mean (SD) weekly use per patient was 5.2 (3.4), and it was persistent over the usage period. Two hundred eighty-five eyes converted while monitored at an annual rate of 2.72% and were treated with a mean (SD) 17.3 (16.5) injections over a mean (SD) 2.7 (2.0) years, with 6.4 (3.1) injections per year for eyes treated for > 1 year. The median VAs at baseline and at final follow-up for eyes that did not convert were 20/27 and 20/34 with a median change of 0.0 letters. The median VAs at baseline, conversion, and final follow-up for eyes that converted during the monitoring period were 20/30, 20/39, and 20/32 with a median change from baseline to conversion, baseline to recent, and conversion to recent of -4, -4, and 0 letters, respectively. Fifty-two percent of conversions detected had a system alert before conversion. Forty-eight percent of patients were detected by symptoms or routine visit. Patients experienced a non-nAMD alert on average every 4.6 years. At conversion and at final follow-up, the proportion (95% CI) of eyes that maintained ≥ 20/40 was 84% (78% to 88%) and 82% (76% to 86%), respectively. CONCLUSIONS: Patients in the FSH monitoring program showed excellent long-term VA years after conversion to nAMD.


Assuntos
Degeneração Macular , Ranibizumab , Idoso , Inibidores da Angiogênese , Hormônio Foliculoestimulante/uso terapêutico , Humanos , Injeções Intravítreas , Degeneração Macular/tratamento farmacológico , Fator A de Crescimento do Endotélio Vascular
3.
J Clin Med ; 10(7)2021 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-33806058

RESUMO

The real-world performance of a home telemonitoring strategy (ForeseeHome AMD Monitoring System®, Notal Vision, Inc.,Manassas VA, USA) was evaluated and compared to the device arm of the AREDS2-HOME study among patients with intermediate AMD (iAMD) who converted to neovascular AMD (nAMD). All patients with confirmed conversion to nAMD who used the home monitoring system from 10/2009 through 9/2018 were identified by Notal Vision Diagnostic Clinic's medical records. Selected outcome variables were evaluated, including visual acuity (VA) at baseline and at conversion, and change in visual acuity (VA) from baseline to time of conversion. In total, 8991 patients performed 3,200,999 tests at a frequency of 5.6 ± 3.2 times/week. The 306 eyes that converted from iAMD to nAMD over the study period (a 2.7% annual rate) were included in the analyses. There was a median (interquartile range) change of -3.0 (0.0-(-10.0)) letters among converted eyes, 81% [95% confidence interval (72-88%)] maintained a VA ≥ 20/40 at the time of conversion, while 69% of the conversion detections were triggered by system alerts. The real-world performance of an at-home testing strategy was similar to that reported for the device arm of the AREDS2-HOME study. The home telemonitoring system can markedly increase early detection of conversion to nAMD.

4.
Retina ; 23(1): 76-9, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12652235

RESUMO

OBJECTIVE: To develop and characterize an infusion cannula that reduces the intraocular jet forces created during fluid-air exchange. METHODS: A new infusion cannula was manufactured by adding a baffle 1.0 mm perpendicular to the distal opening of a 20-gauge infusion. The forces generated by the modified and standard cannulas were measured at a constant air infusion pressure of 50 mmHg by using a force sensor coupled to a schematic eye with eight radial positions from 0 degrees to 180 degrees along the circumference. Five different orientations relative to the baffle support of the modified cannula were evaluated at each position to assess the turbulent flow. RESULTS: The standard cannula produced a maximum force of 0.14 mmHg at 180 degrees from the sensor. The modified cannula generated a maximum pressure of 0.017 mmHg at 67.5 degrees from the sensor. Overall, the force from the modified cannula was an order of magnitude less than the standard infusion cannula (P < 0.01). CONCLUSIONS: The modifications of the new infusion cannula are passive with respect to its surgical performance. However, the additional baffle transforms laminar air currents into turbulent ones and allows dispersion of the jet forces, which should reduce barotrauma and desiccation of the retina during fluid-air exchange.


Assuntos
Cateterismo/instrumentação , Procedimentos Cirúrgicos Oftalmológicos/instrumentação , Fenômenos Biomecânicos , Humanos , Complicações Intraoperatórias/prevenção & controle , Modelos Biológicos , Pressão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...